| Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with … J Delyon, C Mateus, D Lefeuvre, E Lanoy, L Zitvogel, N Chaput, S Roy, ... Annals of Oncology 24 (6), 1697-1703, 2013 | 355 | 2013 |
| Hemophilia A induced by ipilimumab J Delyon, C Mateus, T Lambert New England Journal of Medicine 365 (18), 1747-1748, 2011 | 115 | 2011 |
| Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy E Ghisoni, A Wicky, H Bouchaab, M Imbimbo, J Delyon, BG Moura, ... European Journal of Cancer 149, 153-164, 2021 | 98 | 2021 |
| Survival after fulminant myocarditis induced by immune-checkpoint inhibitors D Arangalage, J Delyon, M Lermuzeaux, K Ekpe, S Ederhy, C Pages, ... Annals of internal medicine 167 (9), 683-684, 2017 | 70 | 2017 |
| Atypical BRAF and NRAS Mutations in Mucosal Melanoma N Dumaz, F Jouenne, J Delyon, S Mourah, A Bensussan, C Lebbé Cancers 11 (8), 1133, 2019 | 60 | 2019 |
| STAT3 mediates nilotinib response in KIT-altered melanoma: a phase II multicenter trial of the French Skin Cancer Network J Delyon, S Chevret, T Jouary, S Dalac, S Dalle, B Guillot, JP Arnault, ... Journal of Investigative Dermatology 138 (1), 58-67, 2018 | 56 | 2018 |
| Turning tumors from cold to inflamed to improve immunotherapy response CL Gerard, J Delyon, A Wicky, K Homicsko, MA Cuendet, O Michielin Cancer treatment reviews 101, 102227, 2021 | 49 | 2021 |
| Low-dose methotrexate-induced skin toxicity: Keratinocyte dystrophy as a histologic marker J Delyon, N Ortonne, E Benayoun, J Moroch, P Wolkenstein, E Sbidian, ... Journal of the American Academy of Dermatology 73 (3), 484-490, 2015 | 49 | 2015 |
| PD-1 blockade with nivolumab in endemic Kaposi sarcoma J Delyon, A Bizot, M Battistella, I Madelaine, L Vercellino, C Lebbé Annals of Oncology 29 (4), 1067-1069, 2018 | 43 | 2018 |
| The ipilimumab lesson in melanoma: achieving long-term survival J Delyon, M Maio, C Lebbe Seminars in oncology 42 (3), 387-401, 2015 | 38 | 2015 |
| Immune checkpoint inhibitor rechallenge in patients with immune-related myositis J Delyon, F Brunet-Possenti, S Leonard-Louis, D Arangalage, M Baudet, ... Annals of the Rheumatic Diseases 78 (11), e129-e129, 2019 | 37 | 2019 |
| Acquired generalized lipodystrophy under immune checkpoint inhibition N Haddad, T Vidal‐Trecan, B Baroudjian, AM Zagdanski, D Arangalage, ... British Journal of Dermatology 182 (2), 477-480, 2020 | 36 | 2020 |
| Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study J Delyon, C Rabate, S Euvrard, CA Harwood, C Proby, AT Güleç, ... Journal of the American Academy of Dermatology 81 (2), 448-455, 2019 | 36 | 2019 |
| Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review A Dupré, JM Michot, A Schoeffler, L Frumholtz, B Baroudjian, J Delyon, ... British Journal of Haematology 189 (5), 985-992, 2020 | 35 | 2020 |
| Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination J Lupu, C Pages, P Laly, J Delyon, M Laloi, A Petit, N Basset-Seguin, ... Melanoma Research 27 (6), 649-652, 2017 | 35 | 2017 |
| Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma J Delyon, C Lebbe, N Dumaz Current Opinion in Oncology 32 (2), 79-84, 2020 | 31 | 2020 |
| Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors A Roger, M Groh, G Lorillon, C Le Pendu, J Maillet, D Arangalage, A Tazi, ... Annals of the Rheumatic Diseases 78 (8), e82-e82, 2019 | 31 | 2019 |
| PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma J Delyon, A Servy, F Laugier, J André, N Ortonne, M Battistella, S Mourah, ... Oncogene 36 (23), 3252-3262, 2017 | 28 | 2017 |
| Immune checkpoint inhibitors in transplantation—a case series and comprehensive review of current knowledge J Delyon, J Zuber, R Dorent, A Poujol-Robert, MN Peraldi, D Anglicheau, ... Transplantation 105 (1), 67-78, 2021 | 26 | 2021 |
| Nivolumab-induced alopecia areata: A reversible factor of good prognosis? M Lakhmiri, B Cavelier-Balloy, C Lacoste, C Cassius, B Baroudjian, ... JAAD case reports 4 (8), 761-765, 2018 | 26 | 2018 |
